LANDSCAPE OF DRIVER MUTATIONS AND THEIR CLINICAL IMPACTS IN CHINESE PEDIATRIC PATIENTS WITH MATURE B‐CELL NON‐HODGKIN'S LYMPHOMA AND T‐CELL LYMPHOBLASTIC LYMPHOMA

Introduction: Mature B-cell non-Hodgkin's lymphoma (MB-NHL) and T-cell lymphoblastic (T-LBL) account for ∼50% ∼20%, respectively, among the different pediatric NHL entities. Our understanding of genetic lesions profiling these patients may help to improve clinical management with lymphomas. The aim this study is analyze mutational status associations between features treatment outcomes in Chinese cohort. Methods: A total 207 treated at multiple centers Children's Lymphoma Collaborative Group (CNCL) from 2017 2023 were included retrospective study. Targeted next-generation sequencing (t-NGS) a panel lymphoma-related genes was performed on tumor samples collected time initial diagnosis refractory or relapse (r/r), correlations somatic mutations survival rates as well other factors analyzed. Results: 136 driver detected entire In 133 MB-NHL patients, most frequently mutated 77 initially diagnostic ID3 (52%), TP53 (47%), CCND3 (30%), ARID1A (29%), DDX3X (27%) (Figure 1a). 56 r/r samples, commonly (84%), followed by (59%), (41%), (32%), (25%) 1b). mutation significantly more frequent than that (p < 0.001) had poor (log-rank p = 0.0013, Figure 1c). Among chimeric antigen receptor (CAR-T) therapy, those exhibited poorer response CAR-T shorter overall compared without such (mOS 180 days, log-rank 0.00081, 1d). 74 T-LBL patients,the NOTCH1 (50%), FBXW7 (26%), JAK1 (16%), NRAS JAK3 (11%) 1e). Genes JAK signaling pathway corresponding western (16% vs. 2%) (11% 5%). Further analysis showed incidence (68% 27%) (37% 12%) patient group remission (n 41) higher 33) 0.005, 0.036, 1f), indicating FBXW7mutations associated good prognosis. Keywords: prognostic biomarkers, immunotherapy, non-Hodgkin (pediatric, adolescent, young adult) No conflicts interests pertinent abstract.